A KDIGO virtual event covering ANCA-Associated Vasculitis (AAV), Complement-Mediated Kidney Disease, IgA Nephropathy (IgAN) and Lupus Nephritis (LN)

Overview

KDIGO GEMs (Guideline Education Meetings) is a new programme offering virtual education on the latest KDIGO Guidelines and evidence-based updates. These interactive events are designed to empower healthcare professionals with the knowledge and tools needed to understand and apply KDIGO recommendations in real-world clinical practice.

By combining cutting-edge guidance with practical insights, KDIGO GEMs provide an engaging platform to enhance clinician expertise, improve patient outcomes and advance global best practices in kidney disease care.

KDIGO is launching our first-ever guideline implementation programme with a focus on glomerular diseases, including topics such as Lupus Nephritis, ANCA-associated Vasculitis, IgA Nephropathy, and Complement-Mediated Kidney Disease. This innovative programme will provide a comprehensive understanding of how to apply KDIGO's evidence-based recommendations and practice points most effectively. 

The presentations will also feature live Q&A sessions for each topic module where the audience can interact with key opinion leaders about the latest state-of-the-art, challenging clinical scenarios and optimal management approaches for the complex patient.

Share this event:

Programme

(Please note this programme is subject to change)

Change your timezone preference

Day 1 (Europe & Asia)

9:00 AM - 10:30 AM (GMT)

Module 1: ANCA-Associated Vasculitis

Chairs: Brad Rovin and Jürgen Floege

  • Background and review of clinical management and trial data – Vladimir Tesar

  • Case-based illustrations – Silke Brix

  • Challenging case scenarios – Duvuru Geetha

  • Live Q&A

 



10:30 AM - 11:45 AM (GMT)

Module 2: Lupus Nephritis

Chairs: Brad Rovin and Jürgen Floege

  • LN management overview and review of recent trial data – Daniel TM Chan

  • General evaluation and management: Case-based illustrations – Juan M. Mejia-Vilet

  • Challenging case scenarios and looking ahead – Liz Lightstone

  • Live Q&A

 




Day 1 (USA & Europe)

5:00 PM - 6:30 PM (GMT)

Module 1: ANCA-Associated Vasculitis

Chairs: Brad Rovin and Jürgen Floege

  • Background and review of clinical management and trial data – Vladimir Tesar

  • Case-based illustrations – Silke Brix

  • Challenging case scenarios – Duvuru Geetha

  • Live Q&A

 



6:30 PM - 7:45 PM (GMT)

Module 2: Lupus Nephritis

Chairs: Brad Rovin and Jürgen Floege

  • LN management overview and review of recent trial data – Daniel TM Chan

  • General evaluation and management: Case-based illustrations – Juan M. Mejia-Vilet

  • Challenging case scenarios and looking ahead – Liz Lightstone

  • Live Q&A

 




Day 2 (Europe & Asia)

9:00 AM - 10:30 AM (GMT)

Module 3: IgAN and IgAV – Broadcast 1 | 09:00 GMT | 17:00 HKT

Chairs: Brad Rovin and Jürgen Floege

  • Pathophysiology and review of trial data – Sydney Tang

  • Case-based illustrations on new treatment paradigm – Dana Rizk

  • Looking ahead – Jonathan Barratt

  • Live Q&A



10:30 AM - 11:45 AM (GMT)

Module 4: Complement-Mediated Kidney Disease – Broadcast 1 | 10:30 GMT | 18:30 HKT

Chairs: Brad Rovin and Jürgen Floege

  • Role of complement in kidney disease – Marina Vivarelli

  • Diagnostic challenges: GDs with membranoproliferative pattern of injury – Daniel Gale

  • Case-based illustrations: ICGN and C3G – Carla Nester

  • Live Q&A




Time Zone: (UTC+00:00) London, Edinburgh [Change Time Zone]

Day 2 (USA & Europe)

5:00 PM - 6:30 PM (GMT)

Module 3: IgAN and IgAV – Broadcast 2 | 17:00 GMT | 12:00 EST

Chairs: Brad Rovin and Jürgen Floege

  • Pathophysiology and review of trial data – Sydney Tang

  • Case-based illustrations on new treatment paradigm – Dana Rizk

  • Looking ahead – Jonathan Barratt

  • Live Q&A



6:30 PM - 7:45 PM (GMT)

Module 4: Complement-Mediated Kidney Disease – Broadcast 2 | 18:30 GMT | 13:30 EST

Chairs: Brad Rovin and Jürgen Floege

  • Role of complement in kidney disease – Marina Vivarelli

  • Diagnostic challenges: GDs with membranoproliferative pattern of injury – Daniel Gale

  • Case-based illustrations: ICGN and C3G – Carla Nester

  • Live Q&A




Time Zone: (UTC+00:00) London, Edinburgh [Change Time Zone]
Register Free

Faculty

Jonathan Barratt
Prof Jonathan Barratt
University of Leicester, UK
Silke Brix
Dr Silke Brix
Manchester University NHS Foundation Trust, UK
Jürgen Floege
Prof Jürgen Floege
University of Aachen, DE
Daniel Gale
Prof Daniel Gale
University College London, UK
Duvuru Geetha
Dr Duvuru Geetha
Johns Hopkins University School of Medicine, US
Liz Lightstone
Prof Liz Lightstone
Imperial College Healthcare NHS Trust, UK
Juan Mejia-Vilet
Dr Juan Mejia-Vilet
National Medical Sciences and Nutrition Institute Salvador Zubiran, MX
Carla Nester
Dr Carla Nester
University of Iowa, US
Dana Rizk
Dr Dana Rizk
University of Alabama at Birmingham, US
Brad Rovin
Prof Brad Rovin
The Ohio State University, US
Sydney Tang
Prof Sydney Tang
The University of Hong Kong, HK
Vladimır Tesar
Prof Vladimır Tesar
Charles University, CZ
Daniel TM Chan
Prof Daniel TM Chan
The University of Hong Kong, HK
Marina Vivarelli
Dr Marina Vivarelli
Bambino Gesù Pediatric Hospital, IT

Learning Objectives

  • Review the latest KDIGO guidance spanning the recent KDIGO GD updates on Lupus Nephritis, ANCA-Associated Vasculitis and IgA Nephropathy, including deliberations from the recent 2022 Complement-Mediated Kidney Disease conference
  • Understand the central takeaways from the KDIGO guideline updates and new developments and key differences from the prior 2021 guideline edition
  • Demonstrate the proper interpretation and application of KDIGO guidance via the use of case-based discussions
  • Address the management of challenging or controversial clinical scenarios
  • Understand the potential and limitations of newer drug combinations
  • Review ongoing studies and new therapeutic agents currently under investigation
  • Identify current gaps in knowledge, standing controversies, and near-term research agenda

Target Audience

  • Nephrologists (including trainees and fellows)
  • Primary Care Physicians
  • Nurses and Allied Health Professionals

KDIGO would like to thank the following partners:

About KDIGO

KDIGO is a global organisation developing and implementing evidence-based clinical practice guidelines in kidney disease. It is an independent, volunteer-led, self-managed foundation incorporated in Belgium and accountable to the public and the patients it serves.

KDIGO has a network of dedicated volunteers from around the world who promote awareness, dissemination, adoption and clinical integration of KDIGO Guidelines both globally and in their respective countries or regions.

For more information on KDIGO, please visit www.kdigo.org.

About Radcliffe CVRM

Radcliffe CVRM is dedicated to supporting learning among cardiologists, nephrologists, diabetologists, endocrinologists, obesity specialists and primary care physicians for better outcomes in patients with cardiovascular, renal and metabolic conditions.

The Radcliffe CVRM platform delivers expert-driven, high-quality content across cardiovascular, renal and metabolic health. It emphasises the growing burden of obesity and its associated conditions, including metabolic dysfunction-associated fatty liver disease (MAFLD). Discover insightful articles, dynamic discussions and the latest research summaries from key conferences, keeping you at the forefront of CVRM care.

Join a Leading Community in CVRM

Connect with a global community dedicated to advancing cardiovascular, renal and metabolic therapy.  Here’s what you’ll find on the platform:

  • Virtual Events and Expert Insights: Engage with leading specialists through interactive events, practical tips and live case presentations that bridge cardiovascular, renal and metabolic care.

  • Latest Conference Highlights: Access concise summaries of pivotal data from major CVRM, nephrology, endocrinology and obesity disease conferences.

  • Innovations in CVRM: Stay updated on the latest technologies, treatment strategies and advancements that are shaping the future of cardiovascular, renal and metabolic care.

For more information on Radcliffe CVRM, please visit www.radcliffecvrm.com.